M. Russano

发表

Exploring the Role of Respiratory Microbiome in Lung Cancer: a Systematic Review.

D. Galetta, S. Novello, M. Tiseo, 2021, Critical reviews in oncology/hematology.

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

G. Tonini, D. Santini, F. Pantano, 2017, Oncotarget.

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

M. Filetti, V. Adamo, L. Antonuzzo, 2022, ESMO Open.

Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

G. Avvisati, G. Cimino, F. Stocchi, 2020, Journal of bone oncology.

Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.

M. Filetti, F. Mazzoni, G. Banna, 2020, Lung cancer.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

L. Antonuzzo, L. Ferrari, D. Melisi, 2017, The oncologist.

Effectiveness of pemetrexed-based chemotherapy and radiation therapy in RET-rearranged lung adenocarcinoma: a mono-institutional case series

B. Vincenzi, G. Tonini, D. Santini, 2021, Precision Cancer Medicine.

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

G. Tonini, D. Santini, F. Pantano, 2017, Oncotarget.

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients

B. Vincenzi, G. Perrone, G. Tonini, 2022, Cancers.

Pazopanib and pancreatic toxicity: a case report

B. Vincenzi, G. Tonini, D. Santini, 2015, BMC Research Notes.

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

L. Antonuzzo, L. Ferrari, D. Melisi, 2018, The oncologist.

Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis.

S. Garattini, M. Aglietta, M. A. Satolli, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis

G. Brandi, S. Garattini, M. Aglietta, 2021, Journal of chemotherapy.

‘Old' and ‘new' drugs for the treatment of cancer pain

V. Denaro, B. Vincenzi, G. Tonini, 2013, Expert opinion on pharmacotherapy.

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

M. Filetti, L. Landi, G. Minuti, 2021, Journal for ImmunoTherapy of Cancer.

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.

M. Filetti, L. Landi, G. Minuti, 2021, European journal of cancer.

Response to cabozantinib in renal cell carcinoma with cardiac metastases.

B. Vincenzi, G. Tonini, D. Santini, 2020, Anti-cancer drugs.

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

B. Vincenzi, G. Perrone, G. Tonini, 2021, Thoracic cancer.

Immunotherapy for colorectal cancer: where are we heading?

S. Garattini, F. Loupakis, D. Santini, 2017, Expert opinion on biological therapy.

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

B. Vincenzi, G. Tonini, A. Cortellini, 2023, Current oncology.

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

N. Tinari, M. Filetti, D. Mallardo, 2020, Oncoimmunology.

Prognostic and predictive factors in pancreatic cancer

A. Minelli, B. Vincenzi, G. Tonini, 2020, Oncotarget.

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

E. Vasile, S. Barni, V. Adamo, 2020, Advances in Therapy.

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

B. Vincenzi, G. Tonini, D. Santini, 2020, Journal of experimental & clinical cancer research : CR.

Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group

Giuseppe Cuccu, A. Mancuso, A. la Sala, 2021, Pain and Therapy.

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

M. Filetti, V. Adamo, M. Tiseo, 2021, Cancer Immunology, Immunotherapy.

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.

M. Filetti, D. Mallardo, P. Ascierto, 2020, European journal of cancer.

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

M. Filetti, D. Mallardo, P. Ascierto, 2020, Journal for ImmunoTherapy of Cancer.

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

M. Filetti, L. Landi, J. Aerts, 2020, Journal for ImmunoTherapy of Cancer.

M. Filetti, L. Landi, F. Cappuzzo, 2020, Clinical lung cancer.

M. Filetti, D. Galetta, V. Adamo, 2020, medRxiv.

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.

M. Filetti, D. Mallardo, P. Ascierto, 2020, European journal of cancer.

Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes

M. Filetti, D. Galetta, G. Banna, 2019, Clinical and Translational Oncology.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

N. Tinari, M. Filetti, M. Tiseo, 2019, Clinical lung cancer.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

N. Tinari, M. Filetti, P. Ascierto, 2019, Journal of Immunotherapy for Cancer.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

N. Tinari, M. Filetti, P. Ascierto, 2019, The oncologist.

Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX

N. Silvestris, A. Brunetti, M. Russano, 2013, Supportive Care in Cancer.

Efficacy of pembrolizumab in lung adenocarcinoma harboring non-V600E BRAF mutation: a case report

B. Vincenzi, G. Tonini, D. Santini, 2021, Precision Cancer Medicine.

Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis

B. Vincenzi, G. Tonini, C. Mallio, 2021, Cancers.

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

E. Vasile, S. Barni, V. Adamo, 2020, Expert opinion on biological therapy.

Facing SARS-CoV-2 outbreak in immunotherapy era

B. Vincenzi, G. Tonini, D. Santini, 2020, Future oncology.

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.

M. Filetti, L. Landi, G. Minuti, 2021, European journal of cancer.

Denosumab for cancer-related bone loss

B. Vincenzi, G. Tonini, D. Santini, 2020, Expert opinion on biological therapy.

Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET-inhibitor pralsetinib.

B. Vincenzi, G. Tonini, D. Santini, 2021, Annals of Oncology.

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

M. Filetti, D. Mallardo, P. Ascierto, 2021, Journal of translational medicine.

"Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study.

S. Scarlata, G. Tonini, P. Crucitti, 2015, Recent patents on anti-cancer drug discovery.

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer

E. Vasile, G. Fasola, G. Brandi, 2014, British Journal of Cancer.

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

M. Filetti, V. Adamo, J. Aerts, 2022, Journal of Hematology & Oncology.

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

B. Vincenzi, G. Tonini, A. Cortellini, 2020, Expert opinion on biological therapy.

Steroid-refractory immune related hepatitis may hide viral re-activation

B. Vincenzi, G. Tonini, P. Gallo, 2020, Future science OA.

Bone metastases in biliary cancers: A multicenter retrospective survey

E. Vasile, S. Barni, G. Brandi, 2018, Journal of bone oncology.

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

M. Filetti, L. Landi, G. Minuti, 2021, Thoracic cancer.

2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts)

E. Vasile, D. Melisi, V. Zagonel, 2015 .

Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A “real-life” study.

E. Vasile, D. Melisi, V. Zagonel, 2015 .

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis

I. Sperduti, F. Morano, D. Sergi, 2016, PloS one.

Pazopanib and pancreatic toxicity: a case report

B. Vincenzi, G. Tonini, D. Santini, 2015, BMC Research Notes.

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

E. Vasile, S. Barni, D. Galetta, 2015, Scientific Reports.

New options and open issues in the management of unresectable stage III and in early-stage NSCLC: a report from an expert panel of Italian medical and radiation oncologists - INTERACTION GROUP.

C. Bennati, C. Greco, E. Olmetto, 2023, Critical reviews in oncology/hematology.

Effective tyrosine kinase inhibitor re-treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer patient: a case report

B. Vincenzi, G. Tonini, D. Santini, 2020 .

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?

B. Vincenzi, G. Tonini, D. Santini, 2020, Journal of Thoracic Oncology.

Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.

M. Filetti, D. Mallardo, P. Ascierto, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.

E. Vasile, D. Melisi, V. Zagonel, 2015 .